Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Ladenburg Thalmann has recently reduced CNS Pharmaceuticals Inc (CNSP) stock to Neutral rating, as announced on December 28, 2020, according to Finviz. Analyst ratings are significant because they ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

HOUSTON - CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced it has received an ...

Ladenburg Thalmann has recently reduced CNS Pharmaceuticals Inc (CNSP) stock to Neutral rating, as announced on December 28, 2020, according to Finviz. Analyst ratings are significant because they ...

CNS Pharmaceuticals (CNSP) announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CNS Pharmaceuticals shares are trading higher by 76% Wednesday morning. The stock faces potential delisting for not meeting ...

HOUSTON - CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced it has received an ...